Compare NGL & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | OLMA |
|---|---|---|
| Founded | 1940 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 751.7M | 725.5M |
| IPO Year | 2011 | 2020 |
| Metric | NGL | OLMA |
|---|---|---|
| Price | $9.80 | $27.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 444.4K | ★ 7.8M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,250,313,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.95 | N/A |
| 52 Week Low | $2.64 | $2.86 |
| 52 Week High | $10.29 | $29.51 |
| Indicator | NGL | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 62.55 | 81.22 |
| Support Level | $9.45 | $26.20 |
| Resistance Level | $10.13 | $28.45 |
| Average True Range (ATR) | 0.41 | 2.87 |
| MACD | -0.13 | 0.57 |
| Stochastic Oscillator | 64.29 | 89.42 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.